skip to Main Content


For a better quality of human life.

R&D in CK Regeon Inc.


We develop First-in-Class drugs targeting CXXC5, a negative feedback regulator of the Wnt/beta-catenin pathway, which is overexpressed in tissues of bald, wounded, obese diabetes and NASH patients.

CXXC5 as a target for development of drugs for treatment of these diseases is confirmed by phenotypes for CXXC5 knock out mice and by developing the PTD-DBM peptide interfering CXXC5 binding to Disheveled (Dvl). By topical application, the peptide induced neogenic hair growth and wound healing via activation of Wnt signaling.

With the development of PTD-DBM as a new concept therapeutics for hair-loss and wound, we further screened and characterized small molecules inhibiting CXXC5-Dvl protein-protein interaction (PPI). Mimetics for the hits were newly synthesized, and several candidates are on the way of pre-clinical stage of drug development for treatment of obesity, diabetes, NASH, hair loss and wound healing.
The candidates are specific to the patients who overexpressed CXXC5 without any noticeable abnormalities.

Back To Top